As of 2025-05-16, the Intrinsic Value of Centrexion Therapeutics Corp (CNTX) is -1.49 USD. This CNTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.75 USD, the upside of Centrexion Therapeutics Corp is -298.6%.

Is CNTX undervalued or overvalued?

Based on its market price of 0.75 USD and our intrinsic valuation, Centrexion Therapeutics Corp (CNTX) is overvalued by 298.6%.

Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.

0.75 USD

Stock Price

-1.49 USD

Intrinsic Value

Intrinsic Value Details

CNTX Intrinsic Value - Valuation Summary

	Range	Selected	Upside
a
Peter Lynch Fair Value	-1.49 - -1.49	-1.49	-298.63%
P/E Multiples	(5.21) - (5.12)	(5.33)	-811.1%

CNTX Intrinsic Value - Peers Comparison

	Range	Selected	Upside
a
Eli Lilly and Co	312.96 - 1,776.56	537.55	-26.7%
Johnson & Johnson	106.3 - 323.83	160.07	7.0%
Merck & Co Inc	96.48 - 157.1	119.60	59.9%
Pfizer Inc	16.41 - 65.97	28.59	26.5%
Bristol-Myers Squibb Co	13.31 - 13.31	13.31	-70.9%
Zoetis Inc	120.93 - 424.36	187.90	17.2%
Royalty Pharma PLC	19.18 - 145.1	38.49	16.2%
Elanco Animal Health Inc	12.02 - 21	15.61	20.7%

CNTX Intrinsic Value - Key Valuation Metrics

Market Cap (mil)	67
Beta	1.14
Outstanding shares (mil)	90
Enterprise Value (mil)	-27

Market risk premium	5.1%
Cost of Equity	6.35%
Cost of Debt	5%
WACC	5.0%